Thalidomide for treating metastatic hepatocellular carcinoma: A pilot study

Korean Journal of Internal Medicine

Volumn 21, Issue 4, 2006, Pages 225-229

  Han, Sang Hoon ^a   Park, Se Hoon ^a   Kim, Jung Ho ^a   Lee, Jong Jun ^a   Kwon, So Young ^a   Kwon, Oh Sang ^a   Kim, Sun Suk ^a   Kim, Ju Hyun ^a   Kim, Keon Kug ^a   Park, Yeon Ho ^a   Lee, Jeong Nam ^a   Nam, Eunmi ^a   Bang, Soo Mee ^a   Cho, Eun Kyung ^a   Shin, Dong Bok ^a   Lee, Jae Hoon ^a  

^a Gachon University College of Medicine   (South Korea)

Author keywords

Carcinoma; Hepatocellular; Thalidomide

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; THALIDOMIDE;

ADULT; ARTICLE; BONE TUMOR; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PILOT STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; BONE NEOPLASMS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PILOT PROJECTS; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33846990952     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2006.21.4.225     Document Type: Article

References (21)

1. Bae JM, Won YJ, Jung KW, Park JG. Annual report of the Korean central cancer registry program 2000. Cancer Res Treat 34:77-83, 2002
2. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers: a clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 105:65-75, 1996
3. Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, Khayat D, Opolon P, Poynard T. Overview of medical treatments in unresectable hepatocellular carcinoma: an impossible meta-analysis? Aliment Pharmacol Ther 12:111-126, 1998
4. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 8:117-136, 1997
5. Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer 40:1474-1484, 2004
6. Jiang W, Lu Z, He Y, Diasio RB. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 3:395-399, 1997
7. Chenivesse X, Franco D, Brechot C. MDR1 (multidrug resistance) gene expression in human primary liver cancer and cirrhosis. J Hepatol 18:168-172, 1993
8. Adlard JW. Thalidomide in the treatment of cancer. Anticancer Drugs 11:787-791, 2000
9. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91:4082-4085, 1994
10. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341:1565-1571, 1999
11. Patt YZ, Hassan MM, Lozano RD, Ellis LM, Peterson JA, Waugh KA. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide. Am J Clin Oncol 23:319-321, 2000
12. Chang JY, Ka WS, Chao TY, Liu TW, Chuang TR, Chen LT. Hepatocellular carcinoma with intra-atrial tumor thrombi: a report of three cases responsive to thalidomide treatment and literature review. Oncology 67:320-326, 2004
13. Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, Hsieh RK. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 10:649-653, 2004
14. Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 65:242-249, 2003
15. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 19:1513-1520, 1994
16. Abou-Alfa GK. Current and novel therapeutics for hepatocellular carcinoma. In: The 40th Am Soc Clin Oncol Education Book. p. 192-197, 2004
17. Masiero L, Figg WD, Kohn EC. New anti-angiogenesis agents: review of the clinical experience with carboxyamido-triazole (CAI), thalidomide, TNP-470 and interleukin-12. Angiogenesis 1:23-35, 1997
18. Patt YZ, Hassan MM, Lozano RD, Nooka AK, Schnirer, II, Zeldis JB, Abbruzzese JL, Brown TD. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 103:749-755, 2005
19. Lin AY, Brophy N, Fisher GA, So S, Biggs C, Yock TI, Levitt L. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 103:119-125, 2005
20. Wadler S. Thalidomide for advanced hepatocellular carcinoma: is this a real alternative? Cancer 103:1-4, 2005
21. Kharbanda PS, Prabhakar S, Chawla YK, Das CP, Syal P. Peripheral neuropathy in liver cirrhosis. J Gastroenterol Hepatol 18:922-926, 2003